These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 6247316)

  • 1. Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins.
    Wise R; Andrews JM; Bedford KA
    J Antimicrob Chemother; 1980 Mar; 6(2):197-206. PubMed ID: 6247316
    [No Abstract]   [Full Text] [Related]  

  • 2. A study of the in vitro activity of cefoperazone: a comparison with other beta-lactam antibiotics.
    Wise R; Gillett AP; Andrews JM
    Clin Ther; 1980; 3(Spec Issue):149-55. PubMed ID: 6446391
    [No Abstract]   [Full Text] [Related]  

  • 3. The in vitro activity of mezlocillin when combined with cefoxitin or clavulanic acid.
    Wise R; Gillett AP; Andrews JM
    J Antimicrob Chemother; 1979 May; 5(3):301-6. PubMed ID: 113377
    [No Abstract]   [Full Text] [Related]  

  • 4. Clavulanic acid in combination with ticarcillin: an in-vitro comparison with other beta-lactams.
    Clarke AM; Zemcov SJ
    J Antimicrob Chemother; 1984 Feb; 13(2):121-8. PubMed ID: 6323375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of BRL 17421 against Haemophilus influenzae, Neisseria gonorrhoeae, and Branhamella catarrhalis.
    Piot P; Van Dyck E
    Antimicrob Agents Chemother; 1982 Jan; 21(1):166-7. PubMed ID: 6805422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The concept of beta-lactamase inhibitor].
    Jarlier V
    Presse Med; 1998 Sep; 27 Suppl 4():17-8. PubMed ID: 9798480
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
    Eliopoulos GM; Klimm K; Ferraro MJ; Jacoby GA; Moellering RC
    Diagn Microbiol Infect Dis; 1989; 12(6):481-8. PubMed ID: 2560420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activity of piperacillin in combination with beta-lactamase inhibitors.
    Neu HC; Fu KP
    Antimicrob Agents Chemother; 1980 Oct; 18(4):582-5. PubMed ID: 6255862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.
    Barry AL; Jones RN; Packer RR
    J Antimicrob Chemother; 1986 Jan; 17(1):125-7. PubMed ID: 3005222
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of the in vitro activity of Bay k 4999 and piperacillin, two new antipseudomonal broad-spectrum penicillins, with other beta-lactam drugs.
    Wise R; Andrews JM; Bedford KA
    Antimicrob Agents Chemother; 1978 Oct; 14(4):549-52. PubMed ID: 102245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of monobactam, SQ 26,776, against Gram-negative bacteria.
    Percival A; Thomas E; Hart CA; Karayiannis P
    J Antimicrob Chemother; 1981 Dec; 8 Suppl E():49-55. PubMed ID: 6799482
    [No Abstract]   [Full Text] [Related]  

  • 12. In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin.
    Wise R; Andrews JM; Bedford KA
    Antimicrob Agents Chemother; 1978 Mar; 13(3):389-93. PubMed ID: 122520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides.
    Retsema JA; English AR; Girard AE
    Antimicrob Agents Chemother; 1980 Apr; 17(4):615-22. PubMed ID: 6249192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of YTR 830.
    Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S
    J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro antibacterial activities of ticarcillin alone and ticarcillin plus clavulanic acid against beta-lactamase producing and non-producing microorganisms.
    Hsueh PR; Chang SC; Chen YC; Hsu LY; Luh KT; Hsieh WC
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1992 Aug; 25(3):149-59. PubMed ID: 1342000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in the potentiation of beta-lactam antibiotic activity by clavulanic acid and sulbactam against multiply antibiotic-resistant bacteria.
    Aldridge KE; Sanders CV; Marier RL
    J Antimicrob Chemother; 1986 Apr; 17(4):463-9. PubMed ID: 3011724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6 -amidinopenicillanic acids--a new group of antibiotics.
    Lund F; Tybring L
    Nat New Biol; 1972 Apr; 236(66):135-7. PubMed ID: 4402006
    [No Abstract]   [Full Text] [Related]  

  • 19. Inconsistency of synergy between the beta-lactamase inhibitor CP-45,899 and beta-lactam antibiotics against multiply drug-resistant Enterobacteriaceae and pseudomonas species.
    Fass RJ
    Antimicrob Agents Chemother; 1981 Feb; 19(2):361-3. PubMed ID: 6289732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clavulanic acid, a novel inhibitor of beta-lactamases.
    Neu HC; Fu KP
    Antimicrob Agents Chemother; 1978 Nov; 14(5):650-5. PubMed ID: 310279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.